Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Cash from Operations: 2023-2025

Historic Cash from Operations for Immunocore Holdings (IMCR) over the last 3 years, with Sep 2025 value amounting to -$4.5 million.

  • Immunocore Holdings' Cash from Operations fell 121.09% to -$4.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.0 million, marking a year-over-year decrease of 64.13%. This contributed to the annual value of $26.1 million for FY2024, which is 786.43% up from last year.
  • According to the latest figures from Q3 2025, Immunocore Holdings' Cash from Operations is -$4.5 million, which was down 117.16% from $26.0 million recorded in Q2 2025.
  • Immunocore Holdings' 5-year Cash from Operations high stood at $26.0 million for Q2 2025, and its period low was -$17.7 million during Q4 2023.
  • Its 3-year average for Cash from Operations is $4.6 million, with a median of $435,000 in 2025.
  • Over the last 5 years, Immunocore Holdings' Cash from Operations had its largest YoY gain of 52,060.00% in 2024, and its largest YoY loss of 143.52% in 2024.
  • Immunocore Holdings' Cash from Operations (Quarterly) stood at -$17.7 million in 2023, then rose by 21.33% to -$14.0 million in 2024, then tumbled by 121.09% to -$4.5 million in 2025.
  • Its Cash from Operations stands at -$4.5 million for Q3 2025, versus $26.0 million for Q2 2025 and $435,000 for Q1 2025.